30 Oct WisBusiness: Exact Sciences is reporting 85 percent revenue growth for the third quarter of 2019, with nearly $219 million in revenue
And the number of Cologuard colon cancer tests performed during the quarter increased 89 percent from the same quarter last year to reach 456,000 tests.
Kevin Conroy, chairman and CEO of Exact Sciences, says the company has screened more than 3 million people over the past five years.
“The team made significant progress enhancing our internal infrastructure with the opening of our new lab and implementation of Epic’s best-in-class electronic health record system,” he said.
Still, the company’s revenue per test declined $13 from the third quarter of 2018 to reach $479. And the average cost to the company per Cologuard test increased $10 over the same period, reaching $114.
Read the full article here.